Take Rhopressa® at
the same time each night

This helps you remember
to take your medication and
simplify your
treatment routine.

About Rhopressa®

Rhopressa® is the first FDA-approved medication in its class to lower elevated eye pressure and may help prevent further vision loss in patients with open-angle glaucoma and ocular hypertension.

New and FDA-approved

Rhopressa® fits any routine

Majority of ocular side effects were mild

What to expect with Rhopressa®

How does Rhopressa® work?

When you have open-angle glaucoma or ocular hypertension, the nerve in your eyes is more susceptible to elevated intraocular pressure (IOP). This pressure, if left untreated, can damage the nerve and may lead to progressive and permanent loss of vision.

Rhopressa® is a prescription eye medication that lowers elevated eye pressure by suppressing the "rho kinase" (ROCK) enzymes responsible for the buildup of fluid and the increase in IOP. This improves the drainage of fluid within the inner eye, which reduces pressure.

Possible side effects

The majority of Rhopressa® side effects are mild. Some side effects may go away without stopping the medication, while others like eye redness go away after stopping treatment. The most common side effect of Rhopressa® was eye redness.

Other common side effects include corneal deposits (verticillate), eye pain, irritation upon instillation, and a red spot on the white of the eye. These are not all of the possible side effects of Rhopressa®.

For more information, refer to the full Prescribing Information. You are encouraged to report side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

Jump-start the conversation with your doctor

Get answers to common questions about Rhopressa® and learn what to ask your doctor at your next eye appointment.

IMPORTANT SAFETY INFORMATION

Dosage and Administration: Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA® is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart.

+

IMPORTANT SAFETY INFORMATION

Dosage and Administration: Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA® is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart.

Warnings and Precautions:

Bacterial Keratitis - There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Adverse reactions: The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA® dosed once daily was conjunctival hyperemia which was reported in 53% of patients. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The corneal verticillata seen in RHOPRESSA®-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes in patients. Most corneal verticillata resolved upon discontinuation of treatment.

INDICATION

RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Dosage and Administration: The recommended dosage is one drop in the affected eye(s) once daily in the evening.